The hybridoma technique set the scene for the development of therapeutic antibodies because it enabled the generation of:
1. totally human antibodies from humanized antibodies. 2. chimeric antibodies from mouse antibodies. 3. mouse monoclonal antibodies from a polyclonal population of mouse B cells. 4. humanized antibodies from chimeric antibodies.